Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Core Insights - Pelareorep demonstrates a favorable safety profile across multiple indications and treatment combinations, with over 1,200 patients dosed, including more than 300 gastrointestinal cancer patients [1][3] - The most common adverse events associated with pelareorep are Grade 1 and 2 symptoms such as fever, chills, fatigue, nausea, vomiting, and diarrhea, with no significant modification of Grade 3 or 4 adverse events from chemotherapy when combined with pelareorep [2][3] - Oncolytics Biotech is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA [5] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent [4] - Pelareorep has shown promising results in various cancer studies, including first-line pancreatic cancer, metastatic breast cancer, and early-phase studies in anal and colorectal cancer [4] - The company is actively pursuing strategic partnerships to enhance development and commercial impact [5]